Treatment Intensification Strategies: Approaches to Optimize Outcomes for High-Risk Localized Disease

How to cite: Randall JM. “Treatment Intensification Strategies: Approaches to Optimize Outcomes for High-Risk Localized Disease.” Grand Rounds in Urology. November 13, 2025. Accessed Oct 2026. https://grandroundsinurology.com/treatment-intensification-strategies-approaches-to-optimize-outcomes-for-high-risk-localized-disease/

Summary

J. Michael Randall, MD, Professor of Medicine, University of California, San Diego, San Diego, California, reviews treatment intensification strategies for patients with high-risk localized prostate cancer, focusing on evidence-supported systemic therapy additions for men pursuing definitive radiation. He begins by defining high-risk localized disease using clinical and pathologic risk factors consistent with guideline-based categorization. Dr. Randall describes high-risk patients as those with clinical stage T3 or T4 disease, grade group 4 or 5, or prostate-specific antigen (PSA) greater than 20. He also reviews a very high-risk category that requires a higher burden of risk features, including combinations of stage, grade, and PSA thresholds.

Dr. Randall outlines that patients with high-risk localized prostate cancer generally pursue either radical prostatectomy or definitive radiation. For those choosing radiation, he emphasizes that outcomes are improved when radiation is combined with androgen deprivation therapy (ADT), and he discusses the rationale for long-term ADT rather than short-term ADT. He notes that patients are often reluctant to accept ADT because of quality of life concerns, and he reviews common side effects, including fatigue, sexual side effects, and metabolic and cardiovascular risks, along with supportive counseling on exercise and coordination with primary care.

Dr. Randall summarizes data supporting long-term ADT durations of 12 to 36 months, with contemporary practice often favoring approximately 18 to 24 months in appropriate patients. Dr. Randall reviews medication options for achieving androgen suppression, including injectable gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LHRH) agonists.

For very high-risk non-metastatic patients pursuing radiation, Dr. Randall discusses adding abiraterone acetate to ADT, describing the trial-supported benefit in metastasis-free survival and the need for monitoring and counseling about adverse effects such as hypertension and hypokalemia. He underlines that intensification prior to radical prostatectomy is not standard outside clinical trials and notes ongoing interest in future phase III results.

About the 32nd Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.